BACKGROUND: Treatment-resistant depression patients show both reduced glucocorticoid receptor function and a hyperactive hypothalamic-pituitary-adrenal axis. However, few studies have examined the role of the mineralocorticoid receptor. This study aimed to evaluate the functional activity of the mineralocorticoid receptor system in regulating the hypothalamic-pituitary-adrenal axis in well-defined treatment-resistant depression patients. MATERIAL AND METHOD: We recruited 24 subjects divided into: (a) treatment-resistant depression; (b) healthy controls. We evaluated: (a) the effect of combined glucocorticoid receptor/mineralocorticoid receptor stimulation with prednisolone; (b) the effect of prednisolone with the mineralocorticoid receptor antagonist spironolactone; and (c) the effect of spironolactone alone. The response of the hypothalamic-pituitary-adrenal axis was measured using salivary cortisol and plasma levels of drugs were also measured. RESULTS: Treatment-resistant depression patients had higher cortisol compared with controls after all challenges. In controls, spironolactone increased cortisol compared to placebo. The co-administration of spironolactone with prednisolone in controls decreases the suppressive effects of prednisolone. In contrast, in treatment-resistant depression, spironolactone did not increase cortisol compared to placebo and spironolactone with prednisolone had no effect on the suppressive effects of prednisolone. Patients with treatment-resistant depression had a reduction in the conversation of spironolactone to the active metabolite canrenone. CONCLUSION: Our data confirmed that treatment-resistant depression is associated with hypercortisolism and these patients no longer show an hypothalamic-pituitary-adrenal response to the administration of a mineralocorticoid receptor antagonist, suggesting that there is a mineralocorticoid receptor malfunctioning, such as a down regulation, however, pharmacokinetics and pharmacodynamics in these subjects could also have had an effect on the lack of mineralocorticoid receptor response.
BACKGROUND: Treatment-resistant depressionpatients show both reduced glucocorticoid receptor function and a hyperactive hypothalamic-pituitary-adrenal axis. However, few studies have examined the role of the mineralocorticoid receptor. This study aimed to evaluate the functional activity of the mineralocorticoid receptor system in regulating the hypothalamic-pituitary-adrenal axis in well-defined treatment-resistant depressionpatients. MATERIAL AND METHOD: We recruited 24 subjects divided into: (a) treatment-resistant depression; (b) healthy controls. We evaluated: (a) the effect of combined glucocorticoid receptor/mineralocorticoid receptor stimulation with prednisolone; (b) the effect of prednisolone with the mineralocorticoid receptor antagonist spironolactone; and (c) the effect of spironolactone alone. The response of the hypothalamic-pituitary-adrenal axis was measured using salivary cortisol and plasma levels of drugs were also measured. RESULTS: Treatment-resistant depressionpatients had higher cortisol compared with controls after all challenges. In controls, spironolactone increased cortisol compared to placebo. The co-administration of spironolactone with prednisolone in controls decreases the suppressive effects of prednisolone. In contrast, in treatment-resistant depression, spironolactone did not increase cortisol compared to placebo and spironolactone with prednisolone had no effect on the suppressive effects of prednisolone. Patients with treatment-resistant depression had a reduction in the conversation of spironolactone to the active metabolite canrenone. CONCLUSION: Our data confirmed that treatment-resistant depression is associated with hypercortisolism and these patients no longer show an hypothalamic-pituitary-adrenal response to the administration of a mineralocorticoid receptor antagonist, suggesting that there is a mineralocorticoid receptor malfunctioning, such as a down regulation, however, pharmacokinetics and pharmacodynamics in these subjects could also have had an effect on the lack of mineralocorticoid receptor response.
Authors: Christopher A Murgatroyd; Catherine J Peña; Giovanni Podda; Eric J Nestler; Benjamin C Nephew Journal: Neuropeptides Date: 2015-05-28 Impact factor: 3.286
Authors: Harald Murck; Thomas Laughren; Femke Lamers; Rosalind Picard; Sebastian Walther; Donald Goff; Stephen Sainati Journal: Innov Clin Neurosci Date: 2015 Mar-Apr
Authors: Christian Otte; Katja Wingenfeld; Linn K Kuehl; Michael Kaczmarczyk; Steffen Richter; Arnim Quante; Francesca Regen; Malek Bajbouj; Frank Zimmermann-Viehoff; Klaus Wiedemann; Kim Hinkelmann Journal: Neuropsychopharmacology Date: 2014-07-18 Impact factor: 7.853
Authors: Luisa Terroni; Edson Amaro; Dan V Iosifescu; Patricia Mattos; Fabio I Yamamoto; Gisela Tinone; Adriana B Conforto; Matildes Fm Sobreiro; Valeri D Guajardo; Mara Cristina S De Lucia; Ayrton C Moreira; Milberto Scaff; Claudia C Leite; Renerio Fraguas Journal: Neuropsychiatr Dis Treat Date: 2015-02-03 Impact factor: 2.570
Authors: Nayara Cobra Barreiro Barroca; Cristiane Von Werne Baes; Camila Maria Severi Martins-Monteverde; Nayanne Beckmann Bosaipo; Marcia Santos da Silva Umeoka; Julian Tejada; José Antunes-Rodrigues; Margaret de Castro; Mario Francisco Juruena; Norberto Garcia-Cairasco; Eduardo Henrique de Lima Umeoka Journal: eNeuro Date: 2021-01-15
Authors: Cristiane von Werne Baes; Camila Maria Severi Martins; Sandra Márcia de Carvalho Tofoli; Mário Francisco Juruena Journal: Front Psychiatry Date: 2014-01-24 Impact factor: 4.157